Arcion gets $8.8M in VC

CMEA Ventures and InterWest Partners have led an $8.8 million A round for Arcion Therapeutics. Arcion has been developing ARC-4558, a topical gel to treat moderate and severe pain caused by diabetic neuropathy. Arcion also has gels in development for other pain indications, looking to compete in the sector by offering a new therapy with fewer side effects.

- see this release for more

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.